Akacia Group CEO, Ronnie Krüger, says that South Africa is the first country in the world to offer the system direct to consumers, which is significant considering we have among the highest asthma death rates globally. “Local stats indicate there are an estimated 18.5 deaths per 100 000 asthma cases, while one in 20 adults and 15% of children live with the respiratory disease. Both the mortality rate and the prevalence of the condition are high and given that asthma cannot be cured, attempts at reducing the disease burden should focus on better management,” says Krüger.

Akacia Medical & Healthcare Group has announced the launch of ADAMM-RSM, a wearable that monitors respiratory functions like asthma.

ADAMM-RSM is a three-part solution that includes the soft comfortable wearable, a free smartphone app (search ADAMM-RSM) and web portal.  The sophistication of the intuitive, algorithm technology allows the user to configure the wearable to monitor and record data relevant to their unique patterns. This can then be reviewed on a dashboard where trends can be tracked, triggers identified, and all the symptom levels can be reviewed at a glance. This data, which is collected and stored in compliance with the POPI Act, can be shared with family members, caregivers and importantly – their treating physician.

The wearable part of the system is attached directly onto the torso using medical grade-peel-and-stick adhesives. It discreetly identifies and monitors respiratory patterns and parameters, including coughing, in context with activity levels, heart rate and skin temperature. It isn’t a diagnostic device and doesn’t treat asthma. It automates the management of the respiratory condition in a way that the asthmatic simply can’t.

By monitoring and recording symptoms, this unique data is used to better understand the disease indicators to get it under control in conjunction with the asthmatic’s preventative and rescue medication. Medication reminders and recording of peak flow meter readings can be enabled as desired.

“As a chronic condition, establishing control requires a solid asthma management plan, which in an ideal world, involves daily measuring and tracking symptoms, and recording and analysing data. These time-consuming activities, often impossible for children, can now be automated and effortlessly managed with ADAMM-RSM.  For caregivers, this also provides objective data around symptom levels, so that there is peace of mind, and a level of freedom knowing that they can understand what’s happening and discuss it with their HCP,” says Krüger.

The effects of chronic respiratory disease can be debilitating, not only for those diagnosed with the disease, but also their caregivers. As a company, HCO believes respiratory conditions are under-served, and that more needs to be done to understand how best to adapt medications and treatment regimens to the individual, so that they can live their best life. The commercialisation of ADAMM-RSM is a considerable first step in achieving this goal.

“Achieving improved symptom control with ADAMM-RSM may reduce high frequency visits to the ER, cut the economic disease burden, and halt needless deaths associated with asthma. We look forward to observing the positive effects this technology will have on controlling asthma,” concludes Krüger.

The device is designed to be used consistently for six to 18 hours every day or night. The more uncontrolled a person’s asthma, the more it should be worn.

For further information go to: www.adamm.co.za